Health Care & Life Sciences » Biotechnology | Trillium Therapeutics Inc.

Trillium Therapeutics Inc. | Ownership

Companies that own Trillium Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Matrix Capital Management Co. LP
2,173,000
15.07%
2,173,000
0.35%
11/30/2017
AWM Investment Co., Inc.
701,138
4.86%
-11,917,286
0.65%
06/30/2018
Cormorant Asset Management LP
600,000
4.16%
600,000
0.26%
05/26/2017
Tekla Capital Management LLC
468,399
3.25%
0
0.09%
06/30/2018
Baker Bros. Advisors LP
409,323
2.84%
409,323
0.02%
12/31/2017
Morgan Stanley & Co. LLC
244,925
1.7%
64,550
0%
06/30/2018
Platinum Investment Management Ltd.
175,339
1.22%
0
0.01%
06/30/2018
Invus Public Equities Advisors LLC
150,000
1.04%
0
0.03%
06/30/2018
Renaissance Technologies LLC
144,000
1%
102,300
0%
06/30/2018
Stanley-Laman Group Ltd.
137,091
0.95%
28,907
0.18%
06/30/2018

About Trillium Therapeutics

View Profile
Address
2488 Dunwin Drive
Mississauga Ontario L5L 1J9
Canada
Employees -
Website http://www.trilliumtherapeutics.com
Updated 07/08/2019
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.